Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial (OXI)
Hydroxychloroquine for the Prevention of Recurrent Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial
Sponsor: Aarne Koskelo Foundation
A PHASE4 clinical study on Acute Coronary Syndrome and Antirheumatic Agents, this trial is completed. The trial is conducted by Aarne Koskelo Foundation and has accumulated 9 data snapshots since 2016. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2020 — Jul 2020 [monthly]
Completed PHASE4
Status: Unknown Status → Completed
▶ Show 4 earlier versions
-
Apr 2020 — Jun 2020 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jun 2018 — Apr 2020 [monthly]
Recruiting PHASE4
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE4
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aarne Koskelo Foundation
- Finnish Cultural Foundation
- Finnish Foundation for Cardiovascular Research
- Helsinki University Central Hospital
- Orion Corporation, Orion Pharma
For direct contact, visit the study record on ClinicalTrials.gov .